You are here

Our science / Clinical Trials / Find a Trial / NCT02947334

Efficacy And Safety Of Bococizumab For Lipid Lowering In Asian Hypercholesterolemia Subjects

Back to Search Print Save as PDF Bookmark Trial

NCT02947334

Last updated on October 10, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Beijing Anzhen Hospital, Capital Medical University
Beijing, Beijing, 100029 China
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Primary Hyperlipidemia or Mixed Dyslipidemia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Males and females at the age or over 18 years of age.

- With primary hyperlipidemia or mixed dyslipidemia.

- Treated with stable daily dose of statins

- At high or very high risk of incurring a CV event

- Fasting LDL-C >=70 mg/dL (1.81 mmol/L) for subjects on the highest approved dose of
statins; Fasting LDL C >=77 mg/dL (1.99 mmol/L) for subjects not on highest approved
dose.

- Fasting TG ≤400 mg/dL (4.51 mmol/L)

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Prior exposure to bococizumab or other investigational PCSK9 inhibitor

- NYHA class IV, or Left Ventricular Ejection Fraction

- Poorly controlled hypertension

- History of hemorrhagic stroke or lacunar infarction resulting in a stroke

- Untreated hyperthyroidism or TSH >1 × ULN

- Undergoing apheresis or have planned start of apheresis.

NCT02947334
Pfizer
Withdrawn
Efficacy And Safety Of Bococizumab For Lipid Lowering In Asian Hypercholesterolemia Subjects

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Locally Advanced or Metastatic Solid Tumors, BRCA 1 Genes
Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors
NCT03565991
All Genders
18+
Years
Multiple Sites
Dermatitis, Atopic Dermatitis, Eczema, Skin Diseases, Genetic Skin Diseases, Inborn Genetic Diseases, Eczematous Skin Diseases, Hypersensitivity, Immediate Hypersensitivity, Immune System Diseases
Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects
NCT03627767
All Genders
12+
Years
Multiple Sites
Partial Seizures Epilepsy, Primary Generalized Tonic-Clonic Seizures Epilepsy
A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures
NCT01463306
All Genders
0+
Years
Multiple Sites
Non Small Cell Lung Cancer ALK Positive or ROS1 Positive
Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive
NCT03178071
All Genders
18+
Years
Multiple Sites
Efficacy And Safety Of Bococizumab For Lipid Lowering In Asian Hypercholesterolemia Subjects
A Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Bococizumab (Pf-04950615) In Asian Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
This study is a Phase 3, double blind, placebo controlled, randomized, stratified, parallel group, multi-center clinical trial designed to compare the efficacy and safety of bococizumab 150 mg SC Q2wks to placebo for LDL-C lowering in subjects with primary hyperlipidemia or mixed dyslipidemia at high or very high risk for CV events. The study will enroll a total of approximately 750 subjects from 4 - 5 Asian countries/areas (including China mainland); of which approximately 600 subjects will be from sites in China. Subjects will be randomized into a bococizumab treatment arm and a placebo arm in a 1:1 ratio.
After providing consent, subjects will enter a screening period of approximately 28 days to verify eligibility for the trial. Eligible subjects will be considered enrolled and progress to the Randomization visit. Results from screening evaluations will be reviewed and only subjects who continue to meet all eligibility criteria will be randomized. Randomized subjects will enter the 12-week treatment period, followed by a 40-week long-term treatment period and a 6 week follow-up, for a total of 58 weeks (approximately 14 months) study participation. Subjects will attend clinic visits as shown in the Schedule of Activities. Subjects will be randomized to receive either 150 mg Q2wks of bococizumab or placebo in a 1:1 ratio. Lipid levels will be blinded to the investigator and staff, subject and sponsor.
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Primary Hyperlipidemia or Mixed Dyslipidemia
  • Biological: Bococizumab
    Bococizumab PFS
    Other Name: RN316
  • Drug: Placebo
    Placebo
  • Experimental: Bococizumab
    Bococizumab Q2wks
    Intervention: Biological: Bococizumab
  • Placebo Comparator: Placebo
    Bococizumab placebo Q2wks
    Intervention: Drug: Placebo
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
May 3, 2019
May 3, 2019   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Males and females at the age or over 18 years of age.
  • With primary hyperlipidemia or mixed dyslipidemia.
  • Treated with stable daily dose of statins
  • At high or very high risk of incurring a CV event
  • Fasting LDL-C >=70 mg/dL (1.81 mmol/L) for subjects on the highest approved dose of statins; Fasting LDL C >=77 mg/dL (1.99 mmol/L) for subjects not on highest approved dose.
  • Fasting TG ?400 mg/dL (4.51 mmol/L)

Exclusion Criteria:

  • Prior exposure to bococizumab or other investigational PCSK9 inhibitor
  • NYHA class IV, or Left Ventricular Ejection Fraction <25%
  • Poorly controlled hypertension
  • History of hemorrhagic stroke or lacunar infarction resulting in a stroke
  • Untreated hyperthyroidism or TSH >1 × ULN
  • Undergoing apheresis or have planned start of apheresis.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
China
 
 
NCT02947334
B1481047
Yes
Not Provided
Plan to Share IPD: Yes
Plan Description: Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/da...
URL: http://
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
November 2017

ICMJE     Data element required by the

International Committee of Medical Journal Editors and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now